Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) ended Friday session in green amid volatile trading. The shares closed up +0.02 points or 0.48% at $4.15 with 1.81 million shares getting traded. Post opening the session at $4.15, the shares hit an intraday low of $4.04 and an intraday high of $4.17 and the price vacillated in this range throughout the day. The company has a market cap of $442.68 million and the numbers of outstanding shares have been calculated to be 105.90 million shares.
Keryx Biopharmaceuticals (KERX) announced it will webcast management presentations at the following investor conferences:
Baird’s 2016 Global Healthcare Conference in New York on Thursday, September 8, 2016 at 9:40 a.m. Eastern Time.
A fireside chat at the Morgan Stanley Global Healthcare Conference in New York on Tuesday, September 13, 2016 at 12:20 p.m. Eastern Time.
Live audio webcasts of the presentations will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under the “webcasts and presentations” page. Archived versions of the webcasts will be available for at least 15 days following the conclusion of the live presentation.
Shares of XOMA Corp (NASDAQ:XOMA) ended Friday session in red amid volatile trading. The shares closed down -0.003 points or -0.53% at $0.560 with 322,479.00 shares getting traded. Post opening the session at $0.58, the shares hit an intraday low of $0.55 and an intraday high of $0.58 and the price vacillated in this range throughout the day. The company has a market cap of $67.89 million and the numbers of outstanding shares have been calculated to be 120.58 million shares.
XOMA Corp (XOMA) discovers, develops, and commercializes antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The companys product candidates include XOMA 358, a human negative allosteric modulating insulin receptor antibody is in phase 2 proof-of-concept study for treating congenital hyperinsulinism and post-meal hypoglycemia in post-bariatric surgery patients; XOMA 129, a potent fragment of a monoclonal antibody is under preclinical testing to treat patients with acute severe hypoglycemia; XOMA 213, a allosteric inhibitor for use in treating prolactinoma and anti-psychotic-induced hyperprolactinemia.